MaxCyte, Inc. announced on January 23, 2024, Cenk Sumen, Ph.D.?s employment as chief scientific officer of the company ended. Dr. Sumen will maintain a relationship with the Company as a member of the company?s Scientific Advisory Board.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
321 GBX | 0.00% |
|
+5.94% | -8.94% |
Jul. 01 | MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 3000E Growth Index | CI |
Jul. 01 | MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2000 Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.94% | 432M | |
+1.15% | 205B | |
+4.69% | 179B | |
+31.83% | 158B | |
+33.39% | 113B | |
+2.81% | 64.93B | |
+22.99% | 56.51B | |
-4.03% | 46.36B | |
-8.60% | 37.07B | |
+2.35% | 36.12B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer